{"organizations": [], "uuid": "10b239d5ba5b5d8df5ee66e2d04ab8cdb8a5299f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180514.html", "section_title": "Archive News &amp; Video for Monday, 14 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pfenex-announces-top-line-pf708-st/brief-pfenex-announces-top-line-pf708-study-results-in-osteoporosis-patients-idUSFWN1SL14H", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfenex Announces Top-Line PF708 Study Results In Osteoporosis Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.479, "site_type": "news", "published": "2018-05-15T04:13:00.000+03:00", "replies_count": 0, "uuid": "10b239d5ba5b5d8df5ee66e2d04ab8cdb8a5299f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pfenex-announces-top-line-pf708-st/brief-pfenex-announces-top-line-pf708-study-results-in-osteoporosis-patients-idUSFWN1SL14H", "ord_in_thread": 0, "title": "BRIEF-Pfenex Announces Top-Line PF708 Study Results In Osteoporosis Patients", "locations": [], "entities": {"persons": [], "locations": [{"name": "osteoporo", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pfenex inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 14 (Reuters) - Pfenex Inc:\n* PFENEX ANNOUNCES POSITIVE TOP-LINE PF708 STUDY RESULTS IN OSTEOPOROSIS PATIENTS, ON-TRACK FOR SUBMISSION OF NEW DRUG APPLICATION IN THIRD QUARTER 2018\n* PFENEX INC - ON-TRACK FOR SUBMISSION TO FDA IN Q3 2018, WITH A POTENTIAL COMMERCIAL LAUNCH IN UNITED STATES AS EARLY AS Q3 2019\n* PFENEX INC - NO IMBALANCES IN SEVERITY OR INCIDENCE OF ADVERSE EVENTS FROM PF708 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T04:13:00.000+03:00", "crawled": "2018-05-15T13:50:49.015+03:00", "highlightTitle": ""}